Jackie Collins


Sacituzumab Govitecan May Be New Standard of Care in Metastatic TNBC

October 19th 2021

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL

September 19th 2021

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer

September 18th 2021

Fam-trastuzumab deruxtecan-nxki demonstrated a clinically meaningful and statistically significant improvement in progression-free survival vs standard of care trastuzumab emtansine for patients with previously treated HER2-positive metastatic breast cancer.

Nivolumab Plus Ipilimumab Response Signals Change for Cytoreductive Nephrectomy in Advanced RCC

September 11th 2021

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

RWE Demonstrates Robust PSA Response and Treatment Adherence of Apalutamide in CRPC

September 10th 2021

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

September 8th 2021

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Tagawa Takes Stock of Future of Sacituzumab Govitecan in Urothelial Carcinoma

August 16th 2021

Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

Sotorasib Flips the Switch for Patients With KRAS G12C-Mutant NSCLC

August 2nd 2021

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

Amivantamab Paves a New Treatment Path for Patients With EGFR Exon 20–Mutant NSCLC

July 14th 2021

Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations.